We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Axovant Gene Therapies Ltd | NASDAQ:AXGT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.10 | 2.09 | 2.11 | 0 | 01:00:00 |
Delaware
|
001-37418
|
85-3863315
|
||||||||||||
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
130 West 42nd Street
26th Floor
New York, New York 10036
(Address of principal executive offices) (Zip Code)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|||||||
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|||||||
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|||||||
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each Class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||||||||||||
Common Stock, par value $0.00001 per share
|
SIOX
|
The Nasdaq Stock Market LLC
|
Name | Votes For | Votes Against | Abstain | Broker Non-Votes | ||||||||||||||||||||||
Frank Torti, M.D. | 32,590,346 | 2,604,442 | 45,629 | 20,036,795 | ||||||||||||||||||||||
Atul Pande, M.D. | 32,919,308 | 2,288,870 | 32,239 | 20,036,795 | ||||||||||||||||||||||
Pavan Cheruvu, M.D. | 34,941,890 | 265,776 | 32,751 | 20,036,795 | ||||||||||||||||||||||
Berndt Modig | 31,867,101 | 3,323,514 | 49,802 | 20,036,795 | ||||||||||||||||||||||
Senthil Sundaram | 34,952,826 | 220,151 | 67,440 | 20,036,795 | ||||||||||||||||||||||
Eric Venker, M.D., Pharm.D. | 32,944,570 | 2,249,184 | 46,663 | 20,036,795 | ||||||||||||||||||||||
Kristiina Vuori, M.D, Ph.D. | 35,008,944 | 191,473 | 40,000 | 20,036,795 |
Votes For | Votes Against | Abstain | ||||||||||||
55,109,854 | 130,758 | 36,600 |
Votes For | Votes Against | Abstain | Broker Non-Votes | |||||||||||||||||
34,125,459 | 1,028,780 | 86,178 | 20,036,795 |
One Year | Two Years | Three Years | Abstain | |||||||||||||||||
19,657,917 | 117,964 | 15,216,054 | 248,482 |
Votes For | Votes Against | Abstain | Broker Non-Votes | |||||||||||||||||
22,911,139 | 12,230,471 | 98,807 | 20,036,795 |
Incorporated by Reference | ||||||||||||||||||||
Exhibit
Number
|
Description
|
Schedule/Form | File No. | Exhibit | Filing Date | |||||||||||||||
10.1 | DEF 14A | 001-37418 | Appendix A | 08/06/2021 |
SIO GENE THERAPIES INC.
|
|||||||||||||||||
Dated:
|
September 24, 2021
|
||||||||||||||||
By:
|
/s/ David Nassif
|
||||||||||||||||
Name:
|
David Nassif
|
||||||||||||||||
Title:
|
Chief Financial Officer and General Counsel
|
1 Year Axovant Gene Therapies Chart |
1 Month Axovant Gene Therapies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions